Your session is about to expire
← Back to Search
Treatment for Non-Small Cell Lung Cancer
Study Summary
This trial is studying a combination of drugs as a treatment for patients with stage III non-small cell lung cancer. The drugs are Carboplatin, Paclitaxel, Durvalumab, and Radiation. All patients will have surgery 4-12 weeks after induction therapy. Patients who remain eligible after surgery will be treated with Durvalumab every 4 weeks for 6 cycles.
- Non-Small Cell Lung Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with a type of lung cancer called NSCLC (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma) and your doctor has reviewed a pathology report from the last 6 months to confirm the diagnosis.Your organs must be working properly based on recent lab tests taken within the last 28 days before enrolling in the trial.You are 18 years old or older.You are expected to live for at least 12 more weeks.The cancer has not spread to other parts of your body.You have superior vena cava syndrome.You have not taken any experimental medication within the last 28 days.You have enough white blood cells called neutrophils in your body, with a count of at least 1.5 K/mm3.You are expected to live for at least 12 more weeks.You cannot have lymph node involvement on the opposite side of your neck or chest.You are able to perform daily activities without assistance or with minimal assistance.You have already received treatment for your non-small cell lung cancer.You have a medical condition, received a treatment, or have a lab result that may affect the study or your ability to take part in it.You have stage III (N2) non-small cell lung cancer (NSCLC) that can be removed through surgery. Your cancer has been confirmed through biopsy and your doctor believes you are healthy enough to undergo the procedure.You have a current or past history of autoimmune or inflammatory disorders, except for certain conditions.You have given written permission for the study to collect and use your personal health information, which will be kept private according to law.You have had a condition called leptomeningeal disease in the past.You have had a previous cancer, unless it is an exception.You have had an organ or bone marrow transplant using donated tissues.
- Group 1: Treatment
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many health facilities are currently testing the efficacy of this research?
"The 4 locations hosting this trial are Houston, Indianapolis, Chicago and an additional unspecified location. To reduce the burden of travelling to a clinic if you decide to join, please select the one nearest your residence."
How many individuals have enrolled in the current experiment?
"At this moment, the trial is not seeking new participants. It was initially put on clinicialtrials.gov on August 2nd 2019, and has been revised most recently as of July 22nd 2022. If you are considering other studies, there are currently 2041 trials open to persons suffering from non-small cell lung carcinoma and 1523 experiments recruiting patients for said treatment."
Is this experiment currently seeking participants?
"This investigation, which was first announced on August 2nd 2019 and modified most recently in July 2022, is not actively recruiting participants. Nonetheless, there are 3,564 additional clinical trials currently enrolling individuals at this moment."
What adverse effects might arise from this treatment regimen?
"While limited evidence exists to verify the treatment's safety, no clinical data has been collected in support of its efficacy; thus it received a score of 2."
What indications commonly necessitate the use of this therapeutic intervention?
"This therapy is an effective means of addressing advanced endometrial cancer. Furthermore, it offers potential relief to individuals suffering from melanoma, neoplasm metastasis, and non-Hodgkin's lymphoma."
Is there any precedent for this particular therapy in the form of prior clinical investigations?
"Currently, the total number of active studies investigating this treatment is 1,523 with 465 in Phase 3. Shanghai has several sites conducting such research; however there are a grand total of 83,540 locations around the world testing it out."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger